Top

Published in:

26-12-2023 | Hyperglycemia | Original Article

Hyperglycemia affects axial signs in patients with Parkinson’s disease through mechanisms of insulin resistance or non-insulin resistance

Authors: Ruidan Wang, Zhaohui Jin, Qiaoxia Zhen, Lin Qi, Cui Liu, Ping Wang, Yonghong Liu, Jinping Fang, Yanjun Liu, Yuan Su, Yixuan Wang, Detao Meng, Hongjiao Yan, Yi Zhen, Zhenzhen Li, Boyan Fang

Published in: Neurological Sciences | Issue 5/2024

Abstract

Objective

To investigate the influence of hyperglycemia on motor symptoms, especially axial signs, and potential mechanisms related to insulin resistance (IR) in patients with Parkinson’s disease (PWP).

Methods

According to glycated hemoglobin (HbA1c) level, PWP were divided into the low-HbA1c and the high-HbA1c groups. Demographic information, glucose metabolism-related variables, Hoehn-Yahr stage, and motor function were compared between the two groups. Correlations between levels of HbA1c and the homeostatic model assessment (HOMA)-IR and motor function in PWP were further analyzed.

Results

HbA1c level was significantly and positively correlated with the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part III score, axial signs subscore, the Timed Get Up and Go test time, the center of pressure displacement of standing with eyes open and closed, and significantly and negatively correlated with the 10-m walk test comfortable gait speed. HOMA-IR level was significantly and negatively correlated with 10-m walk test comfortable gait speed, but not with others.

Conclusions

PWP with high HbA1c showed worse axial symptoms, including dysfunction of automatic walking, dynamic balance, and postural control than those with low HbA1c. In PWP, the effects of hyperglycemia on automatic walking speed may be associated with the IR-related mechanisms, and the effects on dynamic balance and postural control may be related to mechanisms other than IR.

Debû B, De Oliveira GC, Lino JC, Moro E (2018) Managing gait, balance, and posture in Parkinson’s disease. Curr Neurol Neurosci Rep 18:23. https://doi.org/10.1007/s11910-018-0828-4CrossRefPubMed

Kobylecki C, Shiderova I, Boca M, Michou E (2022) Falls risk is predictive of dysphagia in Parkinson’s disease. Neurol Sci 43:1415–1417. https://doi.org/10.1007/s10072-021-05700-6CrossRefPubMed

Barbosa AF, Chen J, Freitag F, Valente D, Souza CO, Voos MC et al (2016) Gait, posture and cognition in Parkinson’s disease. Dement Neuropsychol 10:280–286. https://doi.org/10.1590/s1980-5764-2016dn1004005CrossRefPubMedPubMedCentral

Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE (2008) Predictors of deterioration in health-related quality of life in Parkinson’s disease: results from the DATATOP trial. Mov Disord 23:653–659. https://doi.org/10.1002/mds.21853. (quiz 776)CrossRefPubMed

Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F et al (2018) Diabetes mellitus and Parkinson disease. Neurology 90:e1654–e1662. https://doi.org/10.1212/wnl.0000000000005475CrossRefPubMed

Becker C, Brobert GP, Johansson S, Jick SS, Meier CR (2008) Diabetes in patients with idiopathic Parkinson’s disease. Diabetes Care 31:1808–1812. https://doi.org/10.2337/dc08-0479CrossRefPubMedPubMedCentral

Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S et al (2003) The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60:87–93. https://doi.org/10.1212/wnl.60.1.87CrossRefPubMed

Jeong SM, Han K, Kim D, Rhee SY, Jang W, Shin DW (2020) Body mass index, diabetes, and the risk of Parkinson’s disease. Mov Disord 35:236–244. https://doi.org/10.1002/mds.27922CrossRefPubMed

Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M et al (2022) The impact of type 2 diabetes in Parkinson’s disease. Mov Disord 37:1612–1623. https://doi.org/10.1002/mds.29122CrossRefPubMedPubMedCentral

10.

Ou R, Wei Q, Hou Y, Zhang L, Liu K, Lin J et al (2021) Effect of diabetes control status on the progression of Parkinson’s disease: a prospective study. Ann Clin Transl Neurol 8:887–897. https://doi.org/10.1002/acn3.51343CrossRefPubMedPubMedCentral

11.

Labandeira CM, Fraga-Bau A, Arias Ron D, Alvarez-Rodriguez E, Vicente-Alba P, Lago-Garma J et al (2022) Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing. Neural Regen Res 17:1652–1658. https://doi.org/10.4103/1673-5374.332122CrossRefPubMedPubMedCentral

12.

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675. https://doi.org/10.1016/s0140-6736(17)31585-4CrossRefPubMedPubMedCentral

13.

Bassil F, Fernagut PO, Bezard E, Meissner WG (2014) Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 118:1–18. https://doi.org/10.1016/j.pneurobio.2014.02.005CrossRefPubMed

14.

Li LY, Liu SF, Zhuang JL, Li MM, Huang ZP, Chen YH et al (2022) Recent research progress on metabolic syndrome and risk of Parkinson’s disease. Rev Neurosci. https://doi.org/10.1515/revneuro-2022-0093CrossRefPubMed

15.

Camargo Maluf F, Feder D, de Siqueira A, Carvalho A (2019) Analysis of the relationship between type II diabetes mellitus and Parkinson’s disease: a systematic review. Parkinsons Dis 2019:4951379. https://doi.org/10.1155/2019/4951379CrossRefPubMedPubMedCentral

16.

Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI (2013) Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 19:522–526. https://doi.org/10.1016/j.parkreldis.2013.01.016CrossRefPubMedPubMedCentral

17.

Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G (2012) Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 78:1507–1511. https://doi.org/10.1212/WNL.0b013e3182553cc9CrossRefPubMed

18.

De Iuliis A, Montinaro E, Fatati G, Plebani M, Colosimo C (2022) Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine. Neural Regen Res 17:523–533. https://doi.org/10.4103/1673-5374.320965CrossRefPubMed

19.

Tang Q, Li X, Song P, Xu L (2015) Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: developments in research and prospects for the future. Drug Discov Ther 9:380–385. https://doi.org/10.5582/ddt.2015.01207CrossRefPubMed

20.

Markaki I, Ntetsika T, Sorjonen K, Svenningsson P (2021) Euglycemia indicates favorable motor outcome in Parkinson’s disease. Mov Disord 36:1430–1434. https://doi.org/10.1002/mds.28545CrossRefPubMed

21.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424CrossRefPubMed

22.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653. https://doi.org/10.1002/mds.23429CrossRefPubMed

23.

Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198. https://doi.org/10.1016/0022-3956(75)90026-6CrossRefPubMed

24.

Kuhlman GD, Flanigan JL, Sperling SA, Barrett MJ (2019) Predictors of health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord 65:86–90. https://doi.org/10.1016/j.parkreldis.2019.05.009CrossRefPubMed

25.

Belafsky PC, Mouadeb DA, Rees CJ, Pryor JC, Postma GN, Allen J et al (2008) Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol 117:919–924. https://doi.org/10.1177/000348940811701210CrossRefPubMed

26.

Rosen CA, Lee AS, Osborne J, Zullo T, Murry T (2004) Development and validation of the voice handicap index-10. Laryngoscope 114:1549–1556. https://doi.org/10.1097/00005537-200409000-00009CrossRefPubMed

27.

Lang JT, Kassan TO, Devaney LL, Colon-Semenza C, Joseph MF (2016) Test-retest reliability and minimal detectable change for the 10-meter walk test in older adults with Parkinson’s disease. J Geriatr Phys Ther 39:165–170. https://doi.org/10.1519/jpt.0000000000000068CrossRefPubMed

28.

Podsiadlo D, Richardson S (1991) The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39:142–148. https://doi.org/10.1111/j.1532-5415.1991.tb01616.xCrossRefPubMed

29.

Lee SH, Park SY, Choi CS (2022) Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J 46:15–37. https://doi.org/10.4093/dmj.2021.0280CrossRefPubMed

30.

Uyar M, Lezius S, Buhmann C, Pötter-Nerger M, Schulz R, Meier S et al (2022) Diabetes, glycated hemoglobin (HbA1c), and neuroaxonal damage in Parkinson’s disease (MARK-PD Study). Mov Disord 37:1299–1304. https://doi.org/10.1002/mds.29009CrossRefPubMed

31.

Chohan H, Senkevich K, Patel RK, Bestwick JP, Jacobs BM, Bandres Ciga S et al (2021) Type 2 diabetes as a determinant of Parkinson’s disease risk and progression. Mov Disord 36:1420–1429. https://doi.org/10.1002/mds.28551CrossRefPubMedPubMedCentral

32.

Giuntini M, Baldacci F, Del Prete E, Bonuccelli U, Ceravolo R (2014) Diabetes is associated with postural and cognitive domains in Parkinson’s disease. Results from a single-center study. Parkinsonism Relat Disord 20:671–672. https://doi.org/10.1016/j.parkreldis.2014.02.016CrossRefPubMed

33.

Clark DJ (2015) Automaticity of walking: functional significance, mechanisms, measurement and rehabilitation strategies. Front Hum Neurosci 9:246. https://doi.org/10.3389/fnhum.2015.00246CrossRefPubMedPubMedCentral

34.

Wu T, Hallett M, Chan P (2015) Motor automaticity in Parkinson’s disease. Neurobiol Dis 82:226–234. https://doi.org/10.1016/j.nbd.2015.06.014CrossRefPubMedPubMedCentral

35.

Takakusaki K (2017) Functional neuroanatomy for posture and gait control. J Mov Disord 10:1–17. https://doi.org/10.14802/jmd.16062CrossRefPubMedPubMedCentral

36.

Unger JW, Livingston JN, Moss AM (1991) Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 36:343–362. https://doi.org/10.1016/0301-0082(91)90015-sCrossRefPubMed

37.

White MF, Kahn CR (1994) The insulin signaling system. J Biol Chem 269:1–4CrossRefPubMed

38.

Pang Y, Lin S, Wright C, Shen J, Carter K, Bhatt A et al (2016) Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience 318:157–165. https://doi.org/10.1016/j.neuroscience.2016.01.020CrossRefPubMed

39.

Stouffer MA, Woods CA, Patel JC, Lee CR, Witkovsky P, Bao L et al (2015) Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat Commun 6:8543. https://doi.org/10.1038/ncomms9543CrossRefPubMed

40.

Morris JK, Bomhoff GL, Stanford JA, Geiger PC (2010) Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 299:R1082-1090. https://doi.org/10.1152/ajpregu.00449.2010CrossRefPubMedPubMedCentral

41.

Sharma S, Taliyan R (2018) High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats. Behav Brain Res 351:17–23. https://doi.org/10.1016/j.bbr.2018.05.025CrossRefPubMed

42.

Mustapa A, Justine M, Mohd Mustafah N, Jamil N, Manaf H (2016) Postural control and gait performance in the diabetic peripheral neuropathy: a systematic review. Biomed Res Int 2016:9305025. https://doi.org/10.1155/2016/9305025CrossRefPubMedPubMedCentral

43.

Müller ML, Albin RL, Kotagal V, Koeppe RA, Scott PJ, Frey KA et al (2013) Thalamic cholinergic innervation and postural sensory integration function in Parkinson’s disease. Brain 136:3282–3289. https://doi.org/10.1093/brain/awt247CrossRefPubMedPubMedCentral

44.

Capiotti KM, De Moraes DA, Menezes FP, Kist LW, Bogo MR, Da Silva RS (2014) Hyperglycemia induces memory impairment linked to increased acetylcholinesterase activity in zebrafish (Danio rerio). Behav Brain Res 274:319–325. https://doi.org/10.1016/j.bbr.2014.08.033CrossRefPubMed

45.

Sherin A, Anu J, Peeyush KT, Smijin S, Anitha M, Roshni BT et al (2012) Cholinergic and GABAergic receptor functional deficit in the hippocampus of insulin-induced hypoglycemic and streptozotocin-induced diabetic rats. Neuroscience 202:69–76. https://doi.org/10.1016/j.neuroscience.2011.11.058CrossRefPubMed

Title: Hyperglycemia affects axial signs in patients with Parkinson’s disease through mechanisms of insulin resistance or non-insulin resistance
Authors: Ruidan Wang
Zhaohui Jin
Qiaoxia Zhen
Lin Qi
Cui Liu
Ping Wang
Yonghong Liu
Jinping Fang
Yanjun Liu
Yuan Su
Yixuan Wang
Detao Meng
Hongjiao Yan
Yi Zhen
Zhenzhen Li
Boyan Fang
Publication date: 26-12-2023
Publisher: Springer International Publishing
Keywords: Hyperglycemia
Parkinson Disease
Insulins
Insulins
Published in: Neurological Sciences / Issue 5/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07273-y

Advances in Alzheimer's

Alzheimer's Disease Independent Medical Education

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:

Lilly

Developed by: Springer Healthcare IME

Learn more

2024 ESC Congress

Springer Medicine

Hyperglycemia affects axial signs in patients with Parkinson’s disease through mechanisms of insulin resistance or non-insulin resistance

Abstract

Objective

Methods

Results

Conclusions

Advances in Alzheimer's

2024 ESC Congress

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2024

Correction to: Objective assessment of the effects of opicapone in Parkinson’s disease through kinematic analysis

Amitriptyline induced rosacea-like rash

The Telephone Language Screener (TLS): standardization of a novel telephone-based screening test for language impairment

Advancements in investigating the role of cerebral small vein loss in Alzheimer’s disease–related pathological changes

Efficacy of transauricular vagus nerve stimulation for the treatment of chemotherapy-induced painful peripheral neuropathy: a randomized controlled exploratory study

Association between motor symptoms of Parkinson’s disease and swallowing disorders

Advances in Alzheimer's